[1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600. doi: 10.1210/jc.2004-037210.1210/jc.2004-0372]Search in Google Scholar
[2. Blaton VH, Korita I, Bulo A. How is metabolic syndrome related to dyslipidemia? Biochem Medica 2008;18:14-24. doi: 10.11613/BM.2008.00310.11613/BM.2008.003]Search in Google Scholar
[3. Novelletto BF, Guzzinati S, Avogaro A. Prevalence of metabolic syndrome and its relationship with clinically prevalent cardiovascular disease in the Veneto Region, Northeastern Italy. Metab Syndr Relat Disord 2012;10:56-62. doi: 10.1089/met.2011.006510.1089/met.2011.0065]Search in Google Scholar
[4. Jesmin S, Mia MS, Islam AM, Islam MR, Sultana SN, Zaedi S, Yamaguchi N, Okazaki O, Moroi M, Kimura S, Hiroe M. Prevalence of metabolic syndrome among rural Bangladeshi women. Diabetes Res Clin Pract 2012;95:e7-9. doi: 10.1016/ j.diabres.2011.09.02510.1016/j.diabres.2011.09.025]Search in Google Scholar
[5. Mattoo SK, Chakraborty K, Basu D, Ghosh A, Vijaya Kumar KG, Kulhara P. Prevalence and correlates of metabolic syndrome in alcohol and opioid dependent inpatients. Indian J Med Res 2011;134:341-8. PMID:21985817]Search in Google Scholar
[6. Pećin I, Reiner Ž, Jelaković B. Unos soli, metabolički sindrom i pretilost [Salt intake, metabolic syndrome, and obesity, in Croatian]. [displayed 12 May 2012]. Available at http://www. hcjz.hr/old/clanak.php?id=14134]Search in Google Scholar
[7. Gobel RJ, Jensen SM, Frokiaer H, Molgaard C, Michaelsen KF. Obesity, inflammation and metabolic syndrome in Danish adolescents. Acta Paediatr 2012;101:192-200. doi: 10.1111/ j.1651-2227.2011.02493.x10.1111/j.1651-2227.2011.02493.x]Search in Google Scholar
[8. Olza J, Gil-Campos M, Leis R, Bueno G, Aguilera cm, Valle M, Canete R, Tojo R, Moreno LA, Gil A. Presence of the metabolic syndrome in obese children at prepubertal age. Ann Nutr Metab 2011;58:343-50. doi: 10.1159/00033199610.1159/000331996]Search in Google Scholar
[9. World Health Organisation (WHO). Defi nition, diagnosis and classifi cation of diabetes mellitus and its complications: report of a WHO consultation. Geneva: WHO; 1999.]Search in Google Scholar
[10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation 2005;112:2735-52. PMID: 1615776510.1161/CIRCULATIONAHA.105.169404]Search in Google Scholar
[11. Alberti KGMM, Zimmet PZ, Shaw JE; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new world-wide defi nition from the International Diebetes Federation consensus. Lancet 2005;366:1059-62. doi: 10.1016/S0140-6736(05)67402-810.1016/S0140-6736(05)67402-8]Search in Google Scholar
[12. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3. PMID: 1034234610.1046/j.1464-5491.1999.00059.x10342346]Search in Google Scholar
[13. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629-39. PMID: 2173796010.5551/jat.792221737960]Search in Google Scholar
[14. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M-R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9. doi: 10.2337/diacare.24.4.68310.2337/diacare.24.4.68311315831]Search in Google Scholar
[15. Funahashi T, Matsuzawa Y, Kihara S. Adiponectin as a potential key player in metabolic syndrome - insights into atherosclerosis, diabetes and cancer. Int Cong Series 2004;1262:368-71. doi: 10.1016/j.ics.2004.01.09110.1016/j.ics.2004.01.091]Search in Google Scholar
[16. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Metabolic syndrome, obesity and mortality: impact of cardiorespiratory fitness. Diabetes care 2005;28:391-7. PMID: 1567779810.2337/diacare.28.2.39115677798]Search in Google Scholar
[17. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72. doi: 10.1161/CIRCULATIONAHA.105.53952810.1161/CIRCULATIONAHA.105.53952816275870]Search in Google Scholar
[18. Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009;60(Suppl 7):19-24. PMID: 20388942]Search in Google Scholar
[19. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 2005;30:1-10. PMID: 1535843710.1016/j.psyneuen.2004.05.00715358437]Search in Google Scholar
[20. Staab CA, Maser E. 11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and infl ammation. J Steroid Biochem Mol Biol 2010;119: 56-72.10.1016/j.jsbmb.2009.12.01320045052]Search in Google Scholar
[21. Wang M. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handb Exp Pharmacol 2011;203:127-46. doi: 10.1007/978-3-642-17214-4_610.1007/978-3-642-17214-4_621484570]Search in Google Scholar
[22. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009;94:2692-701. doi: 10.1210/jc.2009-037010.1210/jc.2009-037019470627]Search in Google Scholar
[23. Morton NM. Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010;316:154-64. doi: 10.1016/j. mce.2009.09.024]Search in Google Scholar
[24. Ma X, Lian QQ, Dong Q, Ge RS. Environmental inhibitors of 11β-hydroxysteroid dehydrogenase type 2. Toxicology 2011;285:83-9. doi: 10.1016/j.tox.2011.04.00710.1016/j.tox.2011.04.00721515335]Search in Google Scholar
[25. Park SB, Blumenthal JA, Lee SY, Georgiades A. Association of cortisol and the metabolic syndrome in Korean men and women. J Korean Med Sci 2011;26:914-8. doi: 10.3346/ jkms.2011.26.7.91410.3346/jkms.2011.26.7.914312472221738345]Search in Google Scholar
[26. Grossniklaus DA, Gary RA, Higgins MK, Dunbar SB. Biobehavioral and psychological differences between overweight adults with and without waist circumference risk.Res Nurs Health 2010;33:539-51. doi: 10.1002/nur.2041110.1002/nur.20411]Search in Google Scholar
[27. Mai K, Reinecke F, Andres J, Bobbert T, Kraatz J, Wudy SA, Hartmann MF, Maser-Gluth C, Pfeiffer AF, Spranger J. Effects of hyperlipidaemia on glucocorticoid metabolism: results of a randomized controlled trial in healthy young women. Clin Endocrinol 2011;74:551-7. doi: 10.1111/j.1365-2265.2011.03972.x10.1111/j.1365-2265.2011.03972.x]Search in Google Scholar
[28. Veldhuis JD, Roelfsema F, Iranmanesh A, Carroll BJ, Keenan DM, Pincus SM. Basal, pulsatile, entropic (patterned), and spiky (staccato-like) properties of ACTH secretion: impact of age, gender, and body mass index. J Clin Endocrinol Metab 2009;94:4045-52. doi: 10.1210/jc.2009-114310.1210/jc.2009-1143]Search in Google Scholar
[29. Esteghamati A, Morteza A, Khalilzadeh O, Noshad S, Novin L, Nakhjavani M. Association of serum cortisol levels with parameters of metabolic syndrome in men and women. Clin Invest Med 2011;34:E131-7. PMID: 2163198910.25011/cim.v34i3.15185]Search in Google Scholar
[30. Inder WJ, Obeyesekere VR, Alford FP, Jang C. Skeletal muscle 11βHSD1 activity of nondiabetic subjects is unaltered in central obesity-associated insulin resistance. Horm Metab Res 2011;43:257-60. doi: 10.1055/s-0030-126990510.1055/s-0030-1269905]Search in Google Scholar
[31. Classen JB. Italian pediatric data support hypothesis that simultaneous epidemics of type 1 diabetes and type 2 diabetes/metabolic syndrome/obesity are polar opposite responses (i.e., symptoms) to a primary inflammatory condition. J Pediatr Endocrinol Metab 2011;24:455-6. PMID: 2193258110.1515/jpem.2011.023]Search in Google Scholar
[32. Bjorntorp P. Neuroendocrine perturbations as a cause of insulin resistance. Diabetes Metab Res Rev 1999;15:427-41. PMID: 1063496810.1002/(SICI)1520-7560(199911/12)15:6<427::AID-DMRR68>3.0.CO;2-C]Search in Google Scholar
[33. Duvnjak L, Bulum T, Metelko Ž. Hypertension and metabolic syndrome. Diabetol Croat 2008;37:83-9.]Search in Google Scholar
[34. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-90. PMID: 3310065]Search in Google Scholar
[35. Balbo M, Leproult R, Van Cauter E. Impact of sleep and its disturbances on hypothalamo-pituitary-adrenal axis activity. I n t J E n d o c r i n o l 2 0 1 0 ; 2 0 1 0 : 1 - 1 6 . d o i : 10.1155/2010/759234]Search in Google Scholar
[36. Kohsaka A, Waki H, Cui H, Gouraud SS, Maeda M. Integration of metabolic and cardiovascular diurnal rhythms by circadian clock. Endocr J 2012;59:447-56. PMID: 2236199510.1507/endocrj.EJ12-0057]Search in Google Scholar
[37. Laposky AD, Bass J, Kohsaka A, Turek FW. Sleep and circadian rhythms: Key components in the regulation of energy metabolism. FEBS Lett 2008;582:142-51. doi: 10.1016/j.febslet.2007.06.07910.1016/j.febslet.2007.06.079]Search in Google Scholar
[38. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009;106:4453-8. doi: 10.1073/pnas.080818010610.1073/pnas.0808180106]Search in Google Scholar
[39. Zvonic S, Floyd ZE, Mynatt RL, Gimble JM. Circadian rhythms and the regulation of metabolic tissue function and energy homeostasis. Obesity 2007;15:539-43. doi: 10.1038/ oby.2007.54410.1038/oby.2007.544569323817372301]Search in Google Scholar
[40. Morikawa Y, Nakagawa H, Miura K, Soyama Y, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nogawa K. Effect of shift work on body mass index and metabolic parameters. Scand J Work Environ Health 2007;33:45-50. doi: 10.5271/ sjweh.106310.5271/sjweh.106317353964]Search in Google Scholar
[41. Biggi N, Consonni D, Galluzzo V, Sogliani M, Costa G. Metabolic syndrome in permanent night workers. Chronobiol Int 2008;25:443-54. doi: 10.1080/0742052080211419310.1080/0742052080211419318484373]Search in Google Scholar
[42. Manenschijn L, van Kruysbergen RG, de Jong FH, Koper JW, van Rossum EF. Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J Clin Endocrinol Metab 2011;96:E1862-5. doi: 10.1210/ jc.2011-155110.1210/jc.2011-155121880805]Search in Google Scholar
[43. Gangwisch JE, Heymsfi eld SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, Rundle AG, Zammit GK, Malaspina D. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension 2006;47:833-9. doi: 10.1161/01.HYP.0000217362.34748.e010.1161/01.HYP.0000217362.34748.e016585410]Search in Google Scholar
[44. Vgontzas AN, Lin HM, Papaliaga M, Calhoun S, Vela-Bueno A, Chrousos GP, Bixler EO. Short sleep duration and obesity: the role of emotional stress and sleep disturbances. Int J Obes (Lond) 2008;32:801-9. doi: 10.1038/ijo.2008.410.1038/ijo.2008.418253159]Search in Google Scholar
[45. Kumari M, Badrick E, Ferrie J, Perski A, Marmot M, Chandola T. Self-reported sleep duration and sleep disturbance are independently associated with cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab 2009;94:4801-9. doi: 10.1210/jc.2009-055510.1210/jc.2009-0555279565419850688]Search in Google Scholar
[46. Paslakis G, Gilles M, Lederbogen F, Schilling C, Scharnholz B, Deuschle M. The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients.Eur Arch Psychiatry Clin Neurosci 2011;261:173-7. doi: 10.1007/s00406-010-0164-410.1007/s00406-010-0164-421053006]Search in Google Scholar
[47. Vogelzangs N, Kritchevsky SB, Beekman ATF, Newman AB, Satterfi eld S, Simonsick EM, Yaffe K, Harris TB, Penninx BWJH. Depressive symptoms and change in abdominal obesity in older persons. Arch Gen Psychiatry 2008;65:1386-93. doi: 10.1001/archpsyc.65.12.138610.1001/archpsyc.65.12.1386328545319047525]Search in Google Scholar
[48. Vogelzangs N, Suthers K, Ferrucci L, Simonsick EM, Ble A, Schrager M, Bandinelli S, Lauretani F, Giannelli SV, Penninx BW. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 2007;32:151-9. doi: 10.1016/j.psyneuen.2006.11.00910.1016/j.psyneuen.2006.11.009186846517224244]Search in Google Scholar
[49. Vaccarino V, Bremner DJ. Stress response and the metabolic syndrome. Cardiology/Hospital Physician Cardiology Board Review Manual 2005;11:1-12.]Search in Google Scholar
[50. Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, Maisano C, Jones J, Murrah NV, Vaccarino V. Depressive symptoms and metabolic syndrome: Is infl ammation the underlying link? Biol Psychiatry 2008;64:896-900. doi: 10.1016/j.biopsych.2008.05.01910.1016/j.biopsych.2008.05.019262130918597739]Search in Google Scholar
[51. Vogelzangs N, Duivis HE, Beekman ATF, Kluft C, Neuteboom J, Hoogendijk W, Smit JH, de Jonge P, Penninx BWJH. Association of depressive disorders, depression characteristics and antidepressant medication with infl ammation. Transl Psychiatry 2012;2:e79 doi: 10.1038/ tp.2012.810.1038/tp.2012.8330955622832816]Search in Google Scholar
[52. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008;42:369-81. doi: 10.1080/0004867080196112310.1080/0004867080196112318473255]Search in Google Scholar
[53. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. J Psychopharmacol 2006;20(Suppl 4):15-8. PMID: 1678526510.1177/135978680606604016785265]Search in Google Scholar
[54. Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Heinssen R. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res 2009;115:50-7. doi: 10.1016/j. schres.2009.07.023.]Search in Google Scholar
[55. Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1-4. doi: 10.1016/j.pnpbp.2009.11.00910.1016/j.pnpbp.2009.11.00919922755]Search in Google Scholar
[56. van Reedt Dortland AKB, Vreeburg SA, Giltay EJ, Licht cmM, Vogelzangs N, van Veen T, de Geus EJC, Penninx BJWH, Zitman FG. The impact of stress systems and lifestyle on dyslipidemia and obesity in anxiety and depression. Psychoneuroendocrinology 2013;38:209-18. doi: 10.1016/ j.psyneuen.2012.05.01710.1016/j.psyneuen.2012.05.01722717171]Search in Google Scholar
[57. Albrecht U. Timing to perfection: the biology of central and peripheral circadian clocks. Neuron 2012;74:246-60. doi: 10.1016/j.neuron.2012.04.00610.1016/j.neuron.2012.04.00622542179]Search in Google Scholar
[58. Kohsaka A, Bass J. A sense of time: how molecular clocks organize metabolism. Trends Endocrinol Metab 2007;18:4-11. doi: 10.1016/j.tem.2006.11.00510.1016/j.tem.2006.11.00517140805]Search in Google Scholar
[59. Valenzuela FJ, Torres-Farfan C, Richter HG, Mendez N, Campino C, Torrealba F, Valenzuela GJ, Seron-Ferre M. Clock gene expression in adult primate suprachiasmatic nuclei and adrenal: is the adrenal a peripheral clock responsive to melatonin? Endocrinology 2008;149:1454-61. doi: 10.1210/en.2007-151810.1210/en.2007-151818187542]Search in Google Scholar
[60. Gomez-Abellan P, Hernandez-Morante JJ, Lujan JA, Madrid JA, Garaulet M. Clock genes are implicated in the human metabolic syndrome. Int J Obes (Lond) 2008;32:121-8. PMID: 1765306710.1038/sj.ijo.080368917653067]Search in Google Scholar
[61. Gomez-Santos C, Gomez-Abellan P, Madrid JA, Hernandez- Morante JJ, Lujan JA, Ordovas JM Garaulet M. Circadian rhythm of clock genes in human adipose explants. Obesity 2009;17:1481-5. doi: 10.1038/oby.2009.16410.1038/oby.2009.164442987519478785]Search in Google Scholar
[62. Gambineri A, Tomassoni F, Munarini A, Stimson RH, Mioni R, Pagotto U, Chapman KE, Andrew R, Mantovani V, Pasquali R, Walker BR. A combination of polymorphisms in HSD11B1 associates with in vivo 11β-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol 2011;165:283-92. doi: 10.1530/EJE-11-009110.1530/EJE-11-009121622477]Search in Google Scholar
[63. Torrecilla E, Fernandez-Vazquez G, Vicent D, Sanchez- Franco F, Barabash A, Cabrerizo L, Sanchez-Pernaute A, Torres AJ, Rubio MA. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes Surg 2012;22:478-86. doi: 10.1007/s11695-011-0524-910.1007/s11695-011-0524-921964795]Search in Google Scholar
[64. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006;580:2917-21. doi: 10.1016/j. febslet.2006.04.028]Search in Google Scholar
[65. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, Arita Y, Kihara S, Matsuzawa Y. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Internal Med 1999;38:202-6. PMID: 1022568810.2169/internalmedicine.38.20210225688]Search in Google Scholar
[66. Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and infl ammation. Thromb Haemost 2005;94:1190-5. PMID: 1641139310.1160/TH05-01-0024]Search in Google Scholar
[67. Sorensen TI, Price RA, Stunkard AJ, Schulsinger F. Genetics of obesity in adult adoptees and their biological siblings. BMJ 1989;298:87-90. doi: 10.1136/bmj.298.6666.8710.1136/bmj.298.6666.8718353972493303]Search in Google Scholar
[68. Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest 2011;121:2080-6. doi: 10.1172/JCI4604410.1172/JCI46044310476621633175]Search in Google Scholar
[69. Sebert S, Sharkey D, Budge H, Symonds ME. The early programming of metabolic health: is epigenetic setting the missing link? Am J Clin Nutr 2011;94(Suppl 6):1953S-8S. doi: 10.3945/ajcn.110.00104010.3945/ajcn.110.00104021543542]Search in Google Scholar
[70. McCurdy CE, Bishop JM, Williams SM, Grayson BE, Smith MS, Friedman JE, Grove KL. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest 2009;119:323-35. doi: 10.1172/JCI32]Search in Google Scholar
[71. de Souza Leao LSC, de Moraes MM, de Carvalho GX, Koifman RJ. Nutritional interventions in Metabolic Syndrome: a systematic review. Arq Bras Cardiol 2011;97:260-5. PMID: 2203069810.1590/S0066-782X2011001200012]Search in Google Scholar
[72. Iovino A, Paquot N, Scheen AJ. Reduction du risque metabolique associe a l’obesite en modulant l’exposition tissulaire au cortisol [Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol, in French]. Rev Med Suisse 2010;6:1608-12. PMID: 20853716]Search in Google Scholar
[73. Su X, Vicker N, Thomas MP, Pradaux-Caggiano F, Halem H, Culler MD, Potter BV. Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitors. ChemMedChem 2011;6:1439-51. doi: 10.1002/ cmdc.20110014410.1002/cmdc.201100144317087621608132]Search in Google Scholar
[74. Su X, Pradaux-Caggiano F, Vicker N, Thomas MP, Halem H, Culler MD, Potter BV. Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β- hydroxysteroid dehydrogenase type 1. ChemMedChem 2011;6:1616-29. doi: 10.1002/cmdc.20110018210.1002/cmdc.201100182317984421714097]Search in Google Scholar
[75. Sun D, Wang M, Wang Z. Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Curr Top Med Chem 2011;11:1464-75. PMID: 2151083810.2174/15680261179586098821510838]Search in Google Scholar
[76. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl 3):S12-23. PMID: 9225172]Search in Google Scholar
[77. Bsataki S. Diabetes mellitus and its treatment. Int J Diabet Metabol 2005;13: 11-34.]Search in Google Scholar
[78. Francetić I, editor. Farmakoterapijski priručnik [Pharmacotherapy Handbook, in Croatian]. 6th ed. Zagreb: Medicinska naklada; 2010.]Search in Google Scholar
[79. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-94. PMID: 1293016110.2165/00003495-200363180-0000112930161]Search in Google Scholar
[80. Sweetman SC, editor. Martindale: The Complete Drug Reference. 35th ed. London: Pharmaceutical Press; 2006.]Search in Google Scholar
[81. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004;22:1453-8. PMID: 1525716210.1097/01.hjh.0000133732.24501.9e15257162]Search in Google Scholar
[82. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423. doi: 10.1136/bmj.326.7404.1423 10.1136/bmj.326.7404.142316226012829554]Search in Google Scholar